Drug Search Results
More Filters [+]

Aspartic acid

Alternative Names: aspartic acid, aspartate, mydayis, dyanavel xr, dyanavel xr 15, dyanavel xr 10, dyanavel xr 20, dyanavel xr 5, plenamine, premasol - sulfite-free (amino acid), trophamine, aminosyn ii, aminosyn-pf, prosol, clinisol, kabiven, perikabiven
Latest Update: 2024-09-27
Latest Update Note: News Article

Product Description

Aspartic acid is a nonessential amino acid. Amino acids are building blocks of proteins. (Sourced from: https://medlineplus.gov/ency/article/002234.htm)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity

Known Adverse Events: Attention Deficit Disorder with Hyperactivity | Insomnia | Tachycardia | Abdominal Pain | Dizziness | Pain Unspecified | Anorexia | Weight Loss

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aspartic acid

Countries in Clinic: Germany, Romania, Ukraine

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Chronic Lymphoid Leukemia|Heart Transplant|Other

Phase 1: Attention Deficit Disorder with Hyperactivity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CL-N-CP-Paed

P2

Not yet recruiting

Other

2026-09-30

VV022-02

P2

Active, not recruiting

Chronic Lymphoid Leukemia

2026-07-31

CL-N-HTX-Paed

P2

Not yet recruiting

Heart Transplant

2025-06-30

DEADA-07-23

P1

Not yet recruiting

Attention Deficit Disorder with Hyperactivity

2024-05-06

Recent News Events